Designing nonionic surfactant vesicles for the delivery of antigens for systemic and alternative delivery routes

Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines

Volumn , Issue , 2013, Pages 205-232

  Wilkhu, Jitinder ^a   Vangala, Anil ^b   Mohammed, Afzal R ^a   Perrie, Yvonne ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891602032     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5070-2_11     Document Type: Chapter

References (95)

1. Ali MH, Kirby DJ, Mohammed AR, Perrie Y (2010) Solubilisation of drugs within liposomal bilayers: alternatives to cholesterol as a membrane stabilising agent. J Pharm Pharmacol 62 (11):1646-1655
2. Allen TM, Hansen CB, de Menezes DEL (1995) Pharmacokinetics of long-circulating liposomes. Adv Drug Deliv Rev 16(2-3):267-284
3. Almeida J, Edwards DC, Brand C, Heath T (1975) Formation of virosomes from influenza subunits and liposomes. Lancet 306(7941):899-901
4. Arunothayanun P, Uchegbu IF, Craig DQM, Turton JA, Florence AT (1999) In vitro/in vivo characterisation of polyhedral niosomes. Int J Pharm 183(1):57-61
5. Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS (1985) The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol 37(4):237-242
6. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A (1985) The preparation and properties of niosomes-non-ionic surfactant vesicles. J Pharm Pharmacol 37(12):863-868
7. Bangham AD, Horne RW (1964) Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 8(5):660-668
8. Barakat HS, Darwish IA, El-Khordagui LK, Khalafallah NM (2009) Development of naftifine hydrochloride alcohol-free niosome gel. Drug Dev Ind Pharm 35(5):631-637
9. Barenholzt Y, Amselem S, Lichtenberg D (1979) A new method for preparation of phospholipid vesicles (liposomes)-French press. FEBS Lett 99(1):210-214
10. Batzri S, Korn ED (1973) Single bilayer liposomes prepared without sonication. Biochim Biophys Acta 298(4):1015-1019
11. Bayindir ZS, Yuksel N (2010) Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci 99(4):2049-2060
12. Bennett E, Mullen AB, Ferro VA (2009) Translational modifications to improve vaccine efficacy in an oral influenza vaccine. Methods 49(4):322-327
13. Bibi S, Kaur R, Henriksen-Lacey M, McNeil SE, Wilkhu J, Lattmann E, Christensen D, Mohammed AR, Perrie Y (2011) Microscopy imaging of liposomes: from coverslips to environmental SEM. Int J Pharm 417(1-2):138-150
14. Biswal S, Murthy PN, Sahu J, Sahoo P, Amir F (2008) Vesicles of non-ionic surfactants (niosomes) and drug delivery potential. Int J Pharm Sci Nanotechnol 1(1):1-8
15. Bramwell VW, Perrie Y (2005) The rational design of vaccines. Drug Discov Today 10 (22):1527-1534
16. Brewer JM, Alexander J (1992) The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology 75(4):570-575
17. Brewer JM, Alexander J (1994) Studies on the adjuvant activity of non-ionic surfactant vesicles: adjuvant-driven IgG2a production independent of MHC control. Vaccine 12 (7):613-619
18. Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J (1996) In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 26 (9):2062-2066
19. Brewer JM, Roberts CW, Stimson WH, Alexander J (1995) Accurate determination of adjuvant-associated protein or peptide by ninhydrin assay. Vaccine 13(15):1441-1444
20. Carafa M, Santucci E, Alhaique F, Coviello T, Murtas E, Riccieri FM, Lucania G, Torrisi MR (1998) Preparation and properties of new unilamellar non-ionic/ionic surfactant vesicles. Int J Pharm 160(1):51-59
21. Chambers MA, Wright DC, Brisker J, Williams A, Hatch G, Gavier-Widen D, Hall G, Marsh PD, Glyn Hewinson R (2004) A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome) protects guinea pigs from lethal tuberculosis. Vaccine 22 (8):1063-1071
22. Conacher M, Alexander J, Brewer JM (2001) Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 19 (20-22):2965-2974
23. Corr SC, Gahan CCGM, Hill C (2008) M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol 52(1):2-12
24. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, Agger EM, Andersen P (2005) Characterization of cationic liposomes based on dimethyldioctadecy-lammonium and synthetic cord factor from M. tuberculosis (trehalose 6,60-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 1718 (1-2):22-31
25. Deamer D, Bangham AD (1976) Large volume liposomes by an ether vaporization method. Biochim Biophys Acta 443(3):629-634
26. Desjardins R, Krzystyniak K, Thérien H-M, Banska W, Tancrede P, Fournier M (1995) Immunoactivating potential of multilamellar liposome vesicles (MLV) in murine popliteal lymph node (PLN) test. Int J Immunopharmacol 17(5):367-374
27. Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao BR, Rambhau D (2002) Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci 251(2):360-365
28. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR (1990) Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches. J Control Release 11(1-3):205-214
29. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 84(21):7413-7417
30. Freitas C, Müller RH (1998) Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharm 168(2):221-229
31. González-Rodríguez M, Rabasco A (2011) Charged liposomes as carriers to enhance the permeation through the skin. Expert Opin Drug Deliv 8(7):857-871
32. Gregoriadis G (1990) Immunological adjuvants: a role for liposomes. Immunology Today 11:89-97
33. Gregoriadis G, Leathwood PD, et al (1971) Enzyme entrapment in liposomes. FEBS Letters 14(2):95-99
34. Guinedi AS, Mortada ND, Mansour S, Hathout RM (2005) Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 306(1-2):71-82
35. Gupta PN, Mishra V, Rawat A, Dubey P, Mahor S, Jain S, Chatterji DP, Vyas SP (2005) Noninvasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm 293(1-2):73-82
36. Handjani-Vila RM, Ribier A, Rondot B, Vanlerberghie G (1979) Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int J Cosmet Sci 1(5):303-314
37. Hong M, Zhu S, Jiang Y, Tang G, Pei Y (2009) Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release 133 (2):96-102
38. Hood E, Gonzalez M, Plaas A, Strom J, VanAuker M (2007) Immuno-targeting of nonionic surfactant vesicles to inflammation. Int J Pharm 339(1-2):222-230
39. Huang Y-Z, Gao J-Q, Chen J-L, Liang W-Q (2006) Cationic liposomes modified with nonionic surfactants as effective non-viral carrier for gene transfer. Colloids Surf B Biointerfaces 49(2):158-164
40. Israelachvili JN, Mitchell DJ (1975) A model for the packing of lipids in bilayer membranes. Biochim Biophys Acta 389(1):13-19
41. Israelachvili JN, Mitchell DJ, Ninham BW (1977) Theory of self-assembly of lipid bilayers and vesicles. Biochim Biophys Acta 470(2):185-201
42. Jadon P, Gajbhiye V, Jadon R, Gajbhiye K, Ganesh N (2009) Enhanced oral bioavailability of griseofulvin via niosomes. AAPS PharmSciTech 10(4):1186-1192
43. Jain S, Singh P, Mishra V, Vyas SP (2005) Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against Hepatitis B. Immunol Lett 101(1):41-49
44. Kensil CR (1996) Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 13 (1-2):1-55
45. Kirby C, Gregoriadis G (1984) Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Nat Biotechnol 2(11):979-984
46. Konnings S, Copland MJ, Davies NM, Rades T (2002) A method for the incorporation of ovalbumin into immune stimulating complexes prepared by the hydration method. Int J Pharm 241(2):385-389
47. Kruger NJ (2002) The Bradford method for protein quantitation. In: Walker JM (ed) The protein protocols handbook. Humana Press, Totowa, pp 15-21
48. Kumar VV (1991) Complementary molecular shapes and additivity of the packing parameter of lipids. Proc Natl Acad Sci U S A 88(2):444-448
49. Lasic DD (1990) On the thermodynamic stability of liposomes. J Colloid Interface Sci 140 (1):302-304
50. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D (1991) Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070(1):187-192
51. Lendemans DG, Egert AM, Hook S, Rades T (2007) Cage-like complexes formed by DOTAP, Quil-A and cholesterol. Int J Pharm 332(1-2):192-195
52. Lendemans DG, Myschik J, Hook S, Rades T (2005) Cationic cage-like complexes formed by DC-cholesterol, Quil-A, and phospholipid. J Pharm Sci 94(8):1794-1807
53. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193(1):265-275
54. Mann JFS, Ferro VA, Mullen AB, Tetley L, Mullen M, Carter KC, Alexander J, Stimson WH (2004) Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin. Vaccine 22(19):2425-2429
55. Mann JFS, Scales HE, Shakir E, Alexander J, Carter KC, Mullen AB, Ferro VA (2006) Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 38(2):90-95
56. Mann JFS, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA (2009) Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27(27):3643-3649
57. Manosroi A, Khanrin P, Lohcharoenkal W, Werner RG, Götz F, Manosroi W, Manosroi J (2010) Transdermal absorption enhancement through rat skin of gallidermin loaded in niosomes. Int J Pharm 392(1-2):304-310
58. Manosroi A, Wongtrakul P, Manosroi J, Sakai H, Sugawara F, Yuasa M, Abe M (2003) Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids Surf B Biointerfaces 30(1-2):129-138
59. Moghaddam B, Ali MH, Wilkhu J, Kirby DJ, Mohammed AR, Zheng Q, Perrie Y (2011) The application of monolayer studies in the understanding of liposomal formulations. Int J Pharm 417(1-2):235-244
60. Mohammed AR, Bramwell VW, Coombes AGA, Perrie Y (2006) Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products. Methods 40(1):30-38
61. Mohammed AR, Bramwell VW, Kirby DJ, McNeil SE, Perrie Y (2010) Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development. Eur J Pharm Biopharm 76(3):404-412
62. Mokhtar M, Sammour OA, Hammad MA, Megrab NA (2008) Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm 361(1-2):104-111
63. Mowat MA (2003) Anatomical basis of tolerance and immunity to intestinal antigens. Nature 3:331-341
64. Murdan S, Gregoriadis G, Florence AT (1999) Sorbitan monostearate/polysorbate 20 organogels containing niosomes: a delivery vehicle for antigens? Eur J Pharm Sci 8(3):177-185
65. New R (1990) Liposomes a practical approach. Oxford University Press, New York, pp 1-32
66. Ning M, Guo Y, Pan H, Yu H, Gu Z (2005) Niosomes with sorbitan monoester as a carrier for vaginal delivery of insulin: studies in rats. Drug Deliv 12(6):399-407
67. Norris DA, Puri N, Sinko PJ (1998) The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev 34(2-3):135-154
68. Obrenovic MM, Perrie Y, Gregoriadis G (1998) Entrapment of plasmid DNA into niosomes: characterization studies. J Pharm Pharmacol 50(S9):155
69. Okada JI, Cohen S, Langer R (1995) In vitro evaluation of polymerized liposomes as an oral drug delivery system. Pharm Res 12(4):576-582
70. Papahadjopoulos D, Vail WJ, Jacobson K, Poste G (1975) Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim Biophys Acta 394(3):483-491
71. Perrie Y, Barralet JE, McNeil S, Vangala A (2004) Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route. Int J Pharm 284(1-2):31-41
72. Perrie Y, Obrenovic M, McCarthy D, Gregoriadis G (2002) Liposome (Lipodine™)-mediated DNA vaccination by the oral route. J Liposome Res 12(1-2):185-197
73. Perrie Y, Rades T (2012) FASTtrack: pharmaceutics-drug delivery and targeting. 2nd edn. Pharmaceutical Press, London
74. Rentel CO, Bouwstra JA, Naisbett B, Junginger HE (1999) Niosomes as a novel peroral vaccine delivery system. Int J Pharm 186(2):161-167
75. Sasaki S, Takeshita F, Xin K-Q, Ishii N, Okuda K (2003) Adjuvant formulations and delivery systems for DNA vaccines. Methods 31(3):243-254
76. Schubert R, Jaroni H, Schoelmerich J, Schmidt KH (1983) Studies on the mechanism of bile salt-induced liposomal membrane damage. Digestion 28(3):181-190
77. Shakweh M, Besnard M, Nicolas V, Fattal E (2005) Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur J Pharm Biopharm 61:1-13
78. Shukla A, Katare OP, Singh B, Vyas SP (2010) M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm 385(1-2):47-52
79. Srinivas S, Kumar YA, Hemanth A, Anitha M (2010) Preparation and evaluation of niosomes containing aceclofenac. Digest J Nanomater Biostruct 5(1):249-254
80. Szoka F, Papahadjopoulos D (1978) Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A 75 (9):4194-4198
81. Szoka F, Papahadjopoulos D (1980) Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 9(1):467-508
82. Tabata Y, Ikada Y (1988) Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9(4):356-362
83. Taylor KMG, Morris RM (1995) Thermal analysis of phase transition behaviour in liposomes. Thermochim Acta 248:289-301
84. Uchegbu IF, Double JA, Turton JA, Florence AT (1995) Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Pharm Res 12(7):1019-1024
85. Uchegbu IF, Duncan R (1997) Niosomes containing N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin (PK1): effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution. Int J Pharm 155(1):7-17
86. Uchegbu IF, Florence AT (1995) Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Colloid Interface Sci 58(1):1-55
87. Uchegbu IF, Vyas SP (1998) Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 172(1-2):33-70
88. van Hal DA, Bouwstra JA, van Rensen A, Jeremiasse E, de Vringer T, Junginger HE (1996) Preparation and characterization of nonionic surfactant vesicles. J Colloid Interface Sci 178 (1):263-273
89. Vangala A, Bramwell VW, McNeil S, Christensen D, Agger EM, Perrie Y (2007) Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release 119(1):102-110
90. Vangala A, Kirby D, Rosenkrands I, Agger EM, Andersen P, Perrie Y (2006) A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J Pharm Pharmacol 58(6):787-799
91. Vyas SP, Singh RP, Jain S, Mishra V, Mahor S, Singh P, Gupta PN, Rawat A, Dubey P (2005) Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm 296(1-2):80-86
92. Wacker M, Schubert R (1998) From mixed micelles to liposomes: critical steps during detergent removal by membrane dialysis. Int J Pharm 162(1-2):171-175
93. Walker W, Brewer JM, Alexander J (1996) Lipid vesicle-entrapped influenza A antigen modulates the influenza A-specific human antibody response in immune reconstituted SCID-human mice. Eur J Immunol 26(7):1664-1667
94. Yoshida H, Lehr CM, Kok W, Junginger HE, Verhoef JC, Bouwstra JA (1992) Niosomes for oral delivery of peptide drugs. J Control Release 21(1-3):145-153
95. Yoshioka T, Sternberg B, Florence AT (1994) Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int J Pharm 105(1):1-6